Stock price when the opinion was issued
Shares are down because the market fears they will do a tie-up deal with Humana, but CI bowed out. This is good given Human's problems. Managers are excellent, making good deals. EPS grew 13% compounded annual growth rate from 2013-2023. Are buying back shares and pay a dividend.
(Analysts’ price target is $397.05)
(A Top Pick Sept 20/16. Up 43%.) He continues to like the US healthcare sector. In the US, if over 65 years of age, you spend 3X as much on healthcare as under the age of 65. This company doesn’t have much exposure to the Affordable Care Act and is well positioned to benefit from those trends.